Results 11 to 20 of about 119,519 (336)
Janus Kinase Inhibitors and Cell Therapy [PDF]
Frontiers in Immunology, 2021 Cellular therapies such as allogeneic hematopoietic stem cell transplantation (HSCT) and immune-effector cell therapy (IECT) continue to have a critical role in the treatment of patients with high risk malignancies and hematologic conditions.
Amer Assal +2 more
doaj +3 more sources
Janus Kinases in Leukemia [PDF]
Cancers, 2021 Janus kinases (JAKs) transduce signals from dozens of extracellular cytokines and function as critical regulators of cell growth, differentiation, gene expression, and immune responses. Deregulation of JAK/STAT signaling is a central component in several human diseases including various types of leukemia and other malignancies and autoimmune diseases ...
Juuli Raivola +3 more
openaire +4 more sources
The Janus kinases (Jaks) [PDF]
Genome Biology, 2004 The Janus kinase (Jak) family is one of ten recognized families of non-receptor tyrosine kinases. Mammals have four members of this family, Jak1, Jak2, Jak3 and Tyrosine kinase 2 (Tyk2). Birds, fish and insects also have Jaks. Each protein has a kinase domain and a catalytically inactive pseudo-kinase domain, and they each bind cytokine receptors ...
Yamaoka, Kunihiro +5 more
openaire +3 more sources
The use of Tofacitinib in the treatment of inflammatory bowel disease [PDF]
Терапевтический архив, 2019 Major advances in pharmacology of the 21st century include the development of a new class of drugs, which are low-molecular, chemically synthesized molecules (the so-called "small molecules"), the point of application of which is Janus kinase (Janus ...
E L Nasonov +2 more
doaj +1 more source
Emerging Topical and Systemic JAK Inhibitors in Dermatology [PDF]
, 2019 Accumulating data on cellular and molecular pathways help to develop novel therapeutic strategies in skin inflammation and autoimmunity. Examples are psoriasis and atopic dermatitis, two clinically and immunologically well-defined disorders.
Ghoreschi, Kamran +2 more
core +1 more source
Haematologica, 2017 In most patients with primary myelofibrosis, one of three mutually exclusive somatic mutations is detected. In approximately 60% of patients, the Janus kinase 2 gene is mutated, in 20%, the calreticulin gene is mutated, and in 5%, the myeloproliferative ...
Uri Rozovski +10 more
doaj +1 more source
Acta Dermato-Venereologica, 2022 The aim of this study was to compare the efficacies of systemic treatments with dupilumab, tralokinumab and Janus kinase inhibitors for moderate-to-severe atopic dermatitis. A systematic review following Preferred Reporting Items for Systemic Reviews and
Farnam B. Sedeh +3 more
doaj +1 more source
TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death [PDF]
, 2019 BACKGROUND: Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas that arise most commonly in the setting of the Neurofibromatosis Type 1 (NF1) cancer predisposition syndrome.
Bu, Xianzhang +7 more
core +2 more sources
Janus kinase inhibitors: between prescription authorization and reimbursability
Reumatismo, 2023 Following the restrictions on the reimbursability of Janus kinase inhibitors introduced by the Italian Medicines Agency, the Italian Society of Rheumatology has drafted this document to shed light on the clinical conditions and reimbursability criteria ...
F.R. Spinelli +5 more
doaj +1 more source
Leptin signalling, obesity and prostate cancer: molecular and clinical perspective on the old dilemma [PDF]
, 2015 The prevalence of global obesity is increasing. Obesity is associated with general cancer-related morbidity and mortality and is a known risk factor for development of specific cancers.
Alfraidi, Albandri +5 more
core +2 more sources